Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan, Fludarabine, Cyclophosphamide, and HSCT for Multiple Myeloma or Myelofibrosis
NCT03303950Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine, cyclophosphamide in multiple myeloma (MM), myelofibrosis (MF), sponsored by University of Utah. Started Mar 2018; status: terminated.
02
Drugs
busulfanfludarabinecyclophosphamide
03
Conditions
multiple myeloma (MM)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03303950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303950.